CoChat

Spinal cord pathology is ameliorated by P2X7 antagonism in SOD1-G93A mouse model of amyotrophic lateral sclerosis

Open access
Apolloni, Savina, Amadio, Susanna, Parisi, Chiara, Matteucci, Alessandra, Potenza, Rosa Luisa, Armida, Monica, Popoli, Patrizia, D'Ambrosi, Nadia, Volonté, Cinzia · 2014 · Disease Models & Mechanisms
Cited by 118

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

In recent years there has been an increasing awareness on the role of P2X7 receptor for extracellular ATP in modulating physiopathological mechanisms in the CNS. In particular, P2X7 was shown to be implicated in neuropsychiatry, chronic pain, neurodegeneration, neuroinflammation. Remarkably, P2X7 was shown to be a "gene modifier" in amyotrophic lateral sclerosis (ALS): the receptor is up-regulated in spinal cord microglia in human and rat at advanced stages of the disease; in vitro, activation of P2X7 exacerbates pro-inflammatory responses in ALS-microglia, as well as toxicity towards neuronal cells. Despite this detrimental in vitro role of P2X7, in P2X7−/−/SOD1-G93A mice the clinical onset of ALS was significantly accelerated and disease progression worsened, thus indicating that the receptor might have some beneficial effects at least at certain stages of disease. In order to clarify this dual action of P2X7 in ALS pathogenesis, in the present work we used the antagonist Brilliant Blue G (BBG), a blood-brain barrier permeable and safe drug already proven to reduce neuroinflammation in traumatic brain injury, cerebral ischemia/reperfusion, neuropathic pain and experimental autoimmune encephalitis. We tested BBG in SOD1-G93A ALS mouse model at asymptomatic, pre-symptomatic and late pre-symptomatic phases of disease. BBG at late pre-onset significantly enhances motoneuron survival and reduces microgliosis in lumbar spinal cord, modulating inflammatory markers such as NF-κB, NADPH oxidase 2, interleukin-1β, interleukin-10 and brain-derived neurotrophic factor. This is accompanied by delayed onset and improved general conditions and motor performance, in both male and female mice, although survival appears not affected. Our results prove the twofold role of P2X7 in the course of ALS, and establish that P2X7 modulation might represent a promising therapeutic strategy by interfering with the neuroinflammatory component of the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1242/dmm.017038

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 118

Metadata

Authors
Apolloni, S., Amadio, S., Parisi, C., Matteucci, A., Potenza, R. L., Armida, M., Popoli, P., D'Ambrosi, N., & Volonté, C.
Venue
Disease Models & Mechanisms
Published
2014-01-01
Volume
7
Issue
9
Pages
1101-9
ISSN
  • 1754-8403 (ISSN-L)
  • 1754-8411
OpenAlex
W2108602500
Cited by
118
References
12
FWCI
7.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.